none 10.6061/clinics/2015(08)04 Elsevier BV Elsevier 78 77035669 45578 2025102811221600000 10.1016 2025-10-29T07:01:49Z 2015-08-07T10:52:52Z 24 Clinics Clinics 18075932 08 2015 70 8 Beatriz Felicio Ribeiro Eliana C M Miranda Dulcinéia Martins de Albuquerque Márcia T Delamain Gislaine Oliveira-Duarte Maria Helena Almeida Bruna Vergílio Rosana Antunes da Silveira Vagner Oliveira-Duarte Irene Lorand-Metze Carmino A De Souza Katia B B Pagnano 08 2015 550 555 S1807593222013461 S1807593222013461 10.1016/elsevier_cm_policy elsevier.com sciencedirect.com true Elsevier Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors – a single center experience Clinics https://doi.org/10.6061/clinics/2015(08)04 article Copyright © 2015 CLINICS. Published by Elsevier Spain https://www.elsevier.com/tdm/userlicense/1.0/ https://www.elsevier.com/legal/tdmrep-license https://creativecommons.org/licenses/by/4.0/ 10.6061/clinics/2015(08)04 https://linkinghub.elsevier.com/retrieve/pii/S1807593222013461 http://clinics.org.br/uploads/artigos/clin-70-08/cln-70-08-550.pdf https://api.elsevier.com/content/article/PII:S1807593222013461?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S1807593222013461?httpAccept=text/plain https://dul.usage.elsevier.com/doi/ http://www.scielo.br/scielo.php?script=sci_abstract&pid=S1807-59322015000800550&lng=en&nrm=iso http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4518767/?report=classic Leukemia Giles 27 1 107 2013 10.1038/leu.2012.181 Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study Leukemia Hochhaus 22 6 1200 2008 10.1038/leu.2008.84 Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib Blood Milojkovic 119 8 1838 2012 10.1182/blood-2011-10-383000 Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients Blood Baccarani 122 6 872 2013 10.1182/blood-2013-05-501569 European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 J Clin Oncol Hughes 27 25 4204 2009 10.1200/JCO.2009.21.8230 Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase Blood Cortes 110 12 4005 2007 10.1182/blood-2007-03-080838 Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors Blood Baccarani 108 6 1809 2006 10.1182/blood-2006-02-005686 Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet J Clin Oncol Baccarani 27 35 6041 2009 10.1200/JCO.2009.25.0779 Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet Cancer Cortes 106 6 1306 2006 10.1002/cncr.21756 Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal Blood Testoni 114 24 4939 2009 10.1182/blood-2009-07-229864 Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP Rev Bras Hematol Hemoter Machado 33 3 211 2011 10.5581/1516-8484.20110056 Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase – the importance of a major molecular response Blood Cross 82 6 1929 1993 10.1182/blood.V82.6.1929.1929 Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation Blood Hughes 108 1 28 2006 10.1182/blood-2006-01-0092 Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results Blood Branford 102 1 276 2003 10.1182/blood-2002-09-2896 Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood Quintas-Cardama 109 2 497 2007 10.1182/blood-2006-07-035493 Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure Leukemia Giles 24 7 1299 2010 10.1038/leu.2010.110 Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy J Clin Oncol Marin 30 3 232 2012 10.1200/JCO.2011.38.6565 Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors Blood Hughes 116 19 3758 2010 10.1182/blood-2010-03-273979 Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) Leukemia Hanfstein 26 9 2096 2012 10.1038/leu.2012.85 Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) J Clin Oncol Branford 30 35 4323 2012 10.1200/JCO.2011.40.5217 Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib Blood Shah 123 15 2317 2014 10.1182/blood-2013-10-532341 Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study Blood Quintás-Cardama 113 25 6315 2009 10.1182/blood-2008-07-166694 Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy Blood Ibrahim 116 25 5497 2010 10.1182/blood-2010-06-291922 Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy Blood Garg 114 20 4361 2009 10.1182/blood-2009-05-221531 The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up